Elekta AB

Elekta AB

Elekta AB was founded in 1972 by Lars-Olof Brilioth and others as a medical technology firm focused on radiation oncology. The company went public in 1994 and is listed on the Nasdaq Stockholm exchange. Its core products include the Elekta Unity MR-linac, a hybrid radiotherapy and MRI system, and the Leksell Gamma Knife for brain surgery. Elekta's strategy centers on internal product development and clinical partnerships, such as a collaboration with Philips Healthcare for Unity (per Elekta, 2018). Geographically, Elekta generates revenue from Europe, North America, and Asia, with over 40% of sales outside Europe (per Elekta annual report, 2025). The company employs roughly 4,500 people and maintains R&D centers in Sweden, the UK, and China. In May 2025, Elekta announced a EUR 50 million investment in a new manufacturing facility in Stockholm to expand production capacity (per Elekta press release, May 2025). Elekta is structured as a publicly traded company, not a family office or asset manager, meaning its capital is deployed solely into its medical device operations. Unlike private investment firms, Elekta's governance follows Swedish corporate law with a board elected by shareholders, and its financial reports are public. This operating company model separates it from any wealth management or family office functions.